These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15908793)

  • 21. [Multiple myeloma cell line U266 apoptosis induced by velcade].
    Chen LJ; Li JY; Qian SX; Zhu GR; Zheng WJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):696-9. PubMed ID: 16928302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.
    Psallidas I; Karabela SP; Moschos C; Sherrill TP; Kollintza A; Magkouta S; Theodoropoulou P; Roussos C; Blackwell TS; Kalomenidis I; Stathopoulos GT
    Mol Cancer; 2010 Mar; 9():56. PubMed ID: 20219102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.
    Lara PN; Davies AM; Mack PC; Mortenson MM; Bold RJ; Gumerlock PH; Gandara DR
    Semin Oncol; 2004 Feb; 31(1 Suppl 1):40-6. PubMed ID: 14981579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Proteasome inhibitor, bortezomib (Vercade), potently inhibits the growth of adult T-cell leukemia cells].
    Satou Y; Matsuoka M
    Nihon Rinsho; 2004 Jul; 62(7):1363-7. PubMed ID: 15283157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of bortezomib in the treatment of lymphoma.
    Barr P; Fisher R; Friedberg J
    Cancer Invest; 2007 Dec; 25(8):766-75. PubMed ID: 18058474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma.
    Bonvini P; Zorzi E; Basso G; Rosolen A
    Leukemia; 2007 Apr; 21(4):838-42. PubMed ID: 17268529
    [No Abstract]   [Full Text] [Related]  

  • 27. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis.
    Pham LV; Tamayo AT; Yoshimura LC; Lo P; Ford RJ
    J Immunol; 2003 Jul; 171(1):88-95. PubMed ID: 12816986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecule of the month. Bortezomib.
    Drug News Perspect; 2003 Jun; 16(5):324. PubMed ID: 12942163
    [No Abstract]   [Full Text] [Related]  

  • 29. Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.
    Bu R; Hussain AR; Al-Obaisi KA; Ahmed M; Uddin S; Al-Kuraya KS
    Leuk Lymphoma; 2014 Feb; 55(2):415-24. PubMed ID: 23697845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A striking response to bortezomib in a patient with pleural localization of multiple myeloma.
    Mangiacavalli S; Varettoni M; Zappasodi P; Pica G; Lazzarino M; Corso A
    Leuk Res; 2009 Apr; 33(4):577-8. PubMed ID: 18842298
    [No Abstract]   [Full Text] [Related]  

  • 31. The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs.
    Vega MI; Martinez-Paniagua M; Jazirehi AR; Huerta-Yepez S; Umezawa K; Martinez-Maza O; Bonavida B
    Leuk Lymphoma; 2008 Oct; 49(10):1982-94. PubMed ID: 18949621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
    Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
    Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Success in translational research: lessons from the development of bortezomib.
    Sánchez-Serrano I
    Nat Rev Drug Discov; 2006 Feb; 5(2):107-14. PubMed ID: 16518378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Coleman M
    Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
    Zhu H; Zhang L; Dong F; Guo W; Wu S; Teraishi F; Davis JJ; Chiao PJ; Fang B
    Oncogene; 2005 Jul; 24(31):4993-9. PubMed ID: 15824729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.
    Goel A; Spitz DR; Weiner GJ
    J Cell Biochem; 2012 Feb; 113(2):419-25. PubMed ID: 21956712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dissecting bortezomib: development, application, adverse effects and future direction.
    Cao B; Li J; Mao X
    Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current status of new drugs for the treatment of patients with multiple myeloma.
    Kenealy M; Prince HM
    Intern Med J; 2006 Dec; 36(12):781-9. PubMed ID: 17096741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells.
    Shen L; Au WY; Wong KY; Shimizu N; Tsuchiyama J; Kwong YL; Liang RH; Srivastava G
    Mol Cancer Ther; 2008 Dec; 7(12):3807-15. PubMed ID: 19074855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
    Schwartz R; Davidson T
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):14-21. PubMed ID: 15688598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.